Ensysce Enters Final Phase of Breakthrough Opioid Safety Platform, Aiming to Redefine Pain Management
Ensysce Biosciences launches final Phase‑3 trial of its MPAR opioid safety platform, a breakthrough design that limits overdose risk while preserving pain relief.
3 minutes to read